Product Description
Astodrimer gel is a novel drug which demonstrated favourable outcomes for treatment of patients with bacterial vaginosis. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33749959/)
Mechanisms of Action: Bacterial Growth Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Nasal,Vaginal,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Starpharma Pty
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12620001371987 | P1 |
Completed |
COVID-19 |
2021-03-08 |